Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s disease
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
Bluecrux's digital supply chain twin technology, Axon, plays a critical role in Sanofi's digital supply chain transformation.
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
Additional data from APPRAISE ATP trial reinforce modular therapy approach
The award recognizes powerful science–industry collaborations for social good
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer
The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg
Subscribe To Our Newsletter & Stay Updated
